Trial Profile

A Randomized, Open-Label Study of Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Co-Formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once Daily Versus Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Raltegravir 400 mg Twice Daily in Antiretroviral Naive, HIV-1 Infected Subjects

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lopinavir/ritonavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir
Indications HIV-1 infections
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms PROGRESS

13 Feb 2012 Additional location (Poland) added as reported by ClinicalTrials.gov.
23 Oct 2011 Results presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
15 Oct 2011 Health-related quality of life results presented at the 13th European AIDS Conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com